Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the ...

Merck MRK reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.72, which beat the Zacks Consensus Estimate of $1.69. In the year-ago period, management reported adjusted EPS of 3 cents ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for the HPV vaccine there is expected to hurt 2025 revenue, but it still posted a strong ...

HPV vaccines aim to prevent the development of HPV-related cancers by stopping the viral infection from taking hold in the ...

During his time as a vaccine injury attorney, Kennedy launched complaints and lawsuits against Merck, the maker of Gardasil, which was first approved by the Food and Drug Administration in 2006.

Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug ... % in the past year compared with a decline of 3.9% for the industry. Merck MRK stock has declined ...

The latest approval makes it the first HPV vaccine approved for use among males in China. "The approval of GARDASIL for use in males 9-26 years old in China is a significant step forward in advancing ...

Main Camera Triple 50 MP, f/1.8, (wide), 1/1.57", 1.0µm, PDAF, gimbal OIS 16 MP, f/2.2, 60mm (telephoto), 1/3.1", 1.0µm, PDAF, OIS, 2.5x optical zoom 50 MP, f/2.3 ...